Loading
companiesCompany
Aprea Therapeutics
Aprea developed eprenetapopt, a drug meant to restore the function of mutant p53, which failed its phase 3 trial in TP53-mutant myelodysplastic syndromes in 2020; the company now works on ATR and WEE1 inhibitors.
Also called: Aprea Therapeutics, Inc.Aprea
Overview
Aprea Therapeutics, founded in Stockholm and now based in Doylestown, Pennsylvania and listed on Nasdaq, developed eprenetapopt (APR-246), a small molecule intended to refold mutant p53 into its active form. Combined with azacitidine it produced encouraging phase 2 remissions in TP53-mutant myelodysplastic syndromes, but the phase 3 trial missed its complete remission endpoint in December 2020. The company pivoted to DNA damage response drugs, including the ATR inhibitor ATRN-119 and a WEE1 inhibitor. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Doylestown, PA, US
Scorecard
All companies#409of 1244 companies, score 8
- targets +2
- modalities +2
- registry trials +7
- failures -3
0 approved, 0 in phase 3, 0 earlier, 1 targets, 11 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
NegativeSmall molecule (p53 reactivator)
Eprenetapopt (APR-246) was a drug meant to refold mutant p53, the most common broken protein in cancer. Its phase 3 in blood cancer failed in 2020.
Similar pages
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- PersonMarc H.G.P. Raaijmakers
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TreatmentARD103
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TargetSLX4
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TargetDDX41
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
cancers
fronts
targets
drugs
NegativeSmall molecule (p53 reactivator)